Shanghai Changzheng Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1955-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.shczyy.com
Arsenic Trioxide for Structural p53 Mutations
Phase 2
- Conditions
- Refractory Cancerp53 MutationsIntractable CancerArsenic Trioxide
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04695223
- Locations
- 🇨🇳
Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai, China
BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
Early Phase 1
- Conditions
- Multiple Myeloma
- Interventions
- Biological: GC012F injection
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04617704
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Cervical Laminoplasty Versus Laminectomy and Fusion: the Long-term Results Comparison
- Conditions
- Myelopathy Cervical
- Interventions
- Procedure: Cervical laminoplasty surgeryProcedure: Cervical laminectomy and fusion surgery
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04559672
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, China
Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury
Phase 2
- Conditions
- Spinal Cord Injury
- Interventions
- Biological: Autologous bone marrow-derived mononuclear cellsDrug: Placebo
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT04528550
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, China
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
Phase 2
Recruiting
- Conditions
- ToripalimabGastric CancerAnlotinibImmunotherapy
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT04278222
- Locations
- 🇨🇳
Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai, China
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
Phase 2
Completed
- Conditions
- AnlotinibImmunotherapyColorectal CancerSintilimabChemo-free TherapyFirst-line Treatment
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04271813
- Locations
- 🇨🇳
Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai, China
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma
Early Phase 1
- Conditions
- Multiple Myeloma
- Interventions
- Biological: GC012F injection
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04236011
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
EGFR Monoclonal Antibody for Advanced Gastric Cancer
Phase 2
- Conditions
- NimotuzumabGastric CancerCetuximab
- Interventions
- Drug: EGFR antibody and ChemotherapyDrug: Chemotherapy
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04136600
- Locations
- 🇨🇳
Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai, China
Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Diagnostic Test: The level of plasma cfDNA CINs
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04122092
- Locations
- 🇨🇳
Juan Du, Shanghai, China
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04110093
- Locations
- 🇨🇳
Department of Medical Oncology, Shanghai Changzheng Hospital, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath